[go: up one dir, main page]

DE602006013094D1 - Krebsmittel - Google Patents

Krebsmittel

Info

Publication number
DE602006013094D1
DE602006013094D1 DE602006013094T DE602006013094T DE602006013094D1 DE 602006013094 D1 DE602006013094 D1 DE 602006013094D1 DE 602006013094 T DE602006013094 T DE 602006013094T DE 602006013094 T DE602006013094 T DE 602006013094T DE 602006013094 D1 DE602006013094 D1 DE 602006013094D1
Authority
DE
Germany
Prior art keywords
cancer agent
cancer
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006013094T
Other languages
English (en)
Inventor
Koji Yoshinaga
Daisuke Kawasaki
Yutaka Emori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zeria Pharmaceutical Co Ltd
Original Assignee
Zeria Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeria Pharmaceutical Co Ltd filed Critical Zeria Pharmaceutical Co Ltd
Publication of DE602006013094D1 publication Critical patent/DE602006013094D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE602006013094T 2005-01-19 2006-01-16 Krebsmittel Active DE602006013094D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005011158 2005-01-19
PCT/JP2006/300445 WO2006077793A1 (ja) 2005-01-19 2006-01-16 抗腫瘍剤

Publications (1)

Publication Number Publication Date
DE602006013094D1 true DE602006013094D1 (de) 2010-05-06

Family

ID=36692183

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006013094T Active DE602006013094D1 (de) 2005-01-19 2006-01-16 Krebsmittel

Country Status (18)

Country Link
US (5) US20080161293A1 (de)
EP (1) EP1839662B1 (de)
JP (1) JP4957250B2 (de)
KR (1) KR101285047B1 (de)
CN (1) CN101102776B (de)
AU (1) AU2006207152B2 (de)
BR (1) BRPI0606459A2 (de)
CA (1) CA2594482C (de)
DE (1) DE602006013094D1 (de)
DK (1) DK1839662T3 (de)
ES (1) ES2341728T3 (de)
HK (1) HK1116064A1 (de)
PL (1) PL1839662T3 (de)
PT (1) PT1839662E (de)
RU (1) RU2391982C2 (de)
SI (1) SI1839662T1 (de)
TW (1) TWI399206B (de)
WO (1) WO2006077793A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1839662T3 (da) * 2005-01-19 2010-05-10 Zeria Pharm Co Ltd Antitumormiddel
TWI459948B (zh) * 2008-05-15 2014-11-11 Zeria Pharm Co Ltd The use of a 1,5-benzodiazepine derivative or a pharmaceutically acceptable salt thereof for the manufacture of a pain therapeutic agent composition
MX2011001445A (es) 2008-08-05 2011-04-05 Toray Industries Metodo para detectar cancer.
US9416192B2 (en) 2008-08-05 2016-08-16 Toray Industries, Inc. Pharmaceutical composition for treatment and prevention of cancers
JPWO2010113458A1 (ja) 2009-03-31 2012-10-04 ゼリア新薬工業株式会社 １，５−ベンゾジアゼピン誘導体の製造法
PT2741085T (pt) 2011-08-04 2017-06-30 Toray Industries Método para a deteção de cancro prancreático
WO2014014082A1 (ja) 2012-07-19 2014-01-23 東レ株式会社 癌の検出方法
PT2979700T (pt) * 2013-03-27 2018-12-27 Taiho Pharmaceutical Co Ltd Agente antitumoral que inclui cloridrato de irinotecano hidratado em dose baixa
CN105452294B (zh) 2013-08-09 2019-08-02 东丽株式会社 癌的治疗和/或预防用药物组合物
CN103435562B (zh) * 2013-08-26 2016-02-24 华东理工大学 6-取代苯并二氮卓-2,4-二酮类化合物及其用途
ES2870538T3 (es) 2013-11-22 2021-10-27 CL BioSciences LLC Antagonistas de gastrina (EG YF476, netazepida) para el tratamiento y la prevención de la osteoporosis
CN108395410A (zh) * 2018-05-09 2018-08-14 日照市普达医药科技有限公司 一种苯胺喹唑啉化合物及其在抗肿瘤药物中的应用
CN114948927B (zh) * 2021-02-20 2024-10-15 无锡九基生物科技有限公司 一种含亚苄基的3-苯并呋喃酮衍生物在制备抗肿瘤药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5218115A (en) * 1991-04-10 1993-06-08 Merck & Co., Inc. Cholecystokinin antagonists
JPH0840908A (ja) * 1994-07-28 1996-02-13 Yamanouchi Pharmaceut Co Ltd 癌細胞増殖抑制剤
WO1998025911A1 (fr) * 1996-12-10 1998-06-18 Zeria Pharmaceutical Co., Ltd. Derives de 1,5-benzodiazepine
JP2000026434A (ja) * 1998-06-05 2000-01-25 Zeria Pharmaceut Co Ltd 新規１，５−ベンゾジアゼピン誘導体
AU4564200A (en) * 1999-04-29 2000-11-17 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
PT1234818E (pt) * 1999-12-02 2005-01-31 Zeria Pharm Co Ltd Sais de calcio de derivados de 1,5-benzodiazepina, processo para producao dos sais e drogas que os contem
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US20040138207A1 (en) * 2001-05-11 2004-07-15 Mayumi Yamano Antitumor agents
DK1839662T3 (da) * 2005-01-19 2010-05-10 Zeria Pharm Co Ltd Antitumormiddel

Also Published As

Publication number Publication date
EP1839662A1 (de) 2007-10-03
DK1839662T3 (da) 2010-05-10
JPWO2006077793A1 (ja) 2008-06-19
US20180318314A1 (en) 2018-11-08
US20080161293A1 (en) 2008-07-03
US20100143366A1 (en) 2010-06-10
EP1839662A4 (de) 2008-05-21
CA2594482C (en) 2013-10-01
CN101102776B (zh) 2011-08-24
JP4957250B2 (ja) 2012-06-20
KR20070095930A (ko) 2007-10-01
TWI399206B (zh) 2013-06-21
HK1116064A1 (en) 2008-12-19
WO2006077793A1 (ja) 2006-07-27
AU2006207152B2 (en) 2011-02-24
CN101102776A (zh) 2008-01-09
SI1839662T1 (sl) 2010-07-30
EP1839662B1 (de) 2010-03-24
PL1839662T3 (pl) 2010-08-31
KR101285047B1 (ko) 2013-07-10
RU2007131435A (ru) 2009-02-27
AU2006207152A1 (en) 2006-07-27
CA2594482A1 (en) 2006-07-27
US20170151256A1 (en) 2017-06-01
PT1839662E (pt) 2010-04-28
ES2341728T3 (es) 2010-06-25
US20100086553A1 (en) 2010-04-08
BRPI0606459A2 (pt) 2009-06-30
RU2391982C2 (ru) 2010-06-20
TW200637561A (en) 2006-11-01

Similar Documents

Publication Publication Date Title
DE602006000573D1 (de) Gleitelement
DE602006013094D1 (de) Krebsmittel
ATE408603T1 (de) Pyrazolylcarboxanilide
EP1911738A4 (de) Phenoxyalkansäureverbindung
DE602006018635D1 (de) Triarylcarbonsäurederivat
DE602006016294D1 (de) Mammografiegerät
DE602006017712D1 (de) Phenylpyridonderivat
EP1893244A4 (de) Kontrastmittel
DE502006008475D1 (de) Wasserpumpenflügelrad
DK3190106T3 (da) Desferrithiocinpolyether-analoger
DK1921086T3 (da) Antitumormiddel
EP1916896A4 (de) Nichtsteroid-antiandrogene
DK1948360T3 (da) Valsemölle
DK1968973T3 (da) Aryl-isoxazol-4-yl-imidazolderivater
DE602006018502D1 (de) Ng
DE602006011280D1 (de) Lcopolymerkautschukzusammensetzung
EP1894575A4 (de) Therapeutischer wirkstoff gegen krebs
EP1908459A4 (de) Zusammensetzung zur prävention von krebs
EP2111484A4 (de) Polyamin-aufhellungsmittel
DE502006006589D1 (de) Teils
EP1877549A4 (de) Hiv - impfung
DE502006003147D1 (de) Verbundgußplatte
DE602006007836D1 (de) Kontrastmittel
DE602006018473D1 (de) Il-32-modulatoren
FI20051311A0 (fi) Pilkekone

Legal Events

Date Code Title Description
8364 No opposition during term of opposition